<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7489051\results\search\disease\results.xml">
  <result pre="Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) ChoudhryNamrtaâ€ #ZhaoXinâ€¡#XuDanâ€ ZaninMarkÂ§âŠ¥ChenWeisan*âˆ¥YangZifeng*Â§ChenJianxin*â€"/>
  <result pre="Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) ChoudhryNamrtaâ€ #ZhaoXinâ€¡#XuDanâ€ ZaninMarkÂ§âŠ¥ChenWeisan*âˆ¥YangZifeng*Â§ChenJianxin*â€ [â€"/>
  <result pre="for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) ChoudhryNamrtaâ€ #ZhaoXinâ€¡#XuDanâ€ ZaninMarkÂ§âŠ¥ChenWeisan*âˆ¥YangZifeng*Â§ChenJianxin*â€ [â€ ],"/>
  <result pre="Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) ChoudhryNamrtaâ€ #ZhaoXinâ€¡#XuDanâ€ ZaninMarkÂ§âŠ¥ChenWeisan*âˆ¥YangZifeng*Â§ChenJianxin*â€ [â€ ], South"/>
  <result pre="Weisan.Chen@latrobe.edu.au. *Z.Y.: email, jeffyah@163.com. *J.C.: email, jxchen@scau.edu.cn. epub: 2020-08-08acs.jmedchem.0c00626received: 2020-04-16(C)" exact="American" post="Chemical Society, 2020This article is made available via the"/>
  <result pre="declaration of COVID-19 as a global pandemic. Abstract The coronavirus" exact="disease" post="2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus"/>
  <result pre="pandemic. Abstract The coronavirus disease 2019 (COVID-19) caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to more"/>
  <result pre="Abstract The coronavirus disease 2019 (COVID-19) caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) has led to more than"/>
  <result pre="The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) has led to more than 20"/>
  <result pre="size of 27â€&quot;33 kb. They can cause diseases of the" exact="respiratory" post="tract, intestinal tract, liver, and nervous system of many"/>
  <result pre="and HCoV-NL63, which are common and cause mild to moderate" exact="respiratory" post="infections, such as the common cold.1 Two other Î²-CoVs,"/>
  <result pre="infections, such as the common cold.1 Two other Î²-CoVs, severe" exact="acute" post="respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome"/>
  <result pre="such as the common cold.1 Two other Î²-CoVs, severe acute" exact="respiratory" post="syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV"/>
  <result pre="as the common cold.1 Two other Î²-CoVs, severe acute respiratory" exact="syndrome" post="CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV),"/>
  <result pre="Î²-CoVs, severe acute respiratory syndrome CoV (SARS-CoV) and Middle East" exact="respiratory" post="syndrome CoV (MERS-CoV), have zoonotic origins and have been"/>
  <result pre="severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory" exact="syndrome" post="CoV (MERS-CoV), have zoonotic origins and have been linked"/>
  <result pre="8454 confirmed cases and 792 deaths.6 In 2012, Middle East" exact="respiratory" post="syndrome (MERS), caused by MERS-CoV, emerged in the Kingdom"/>
  <result pre="confirmed cases and 792 deaths.6 In 2012, Middle East respiratory" exact="syndrome" post="(MERS), caused by MERS-CoV, emerged in the Kingdom of"/>
  <result pre="subsequently spread to 27 countries.7 MERS presented as a severe" exact="respiratory" post="disease with frequent gastrointestinal and renal complications. As of"/>
  <result pre="spread to 27 countries.7 MERS presented as a severe respiratory" exact="disease" post="with frequent gastrointestinal and renal complications. As of September"/>
  <result pre="Hubei Province, China. 1.2 The COVID-19 Pandemic In December 2019," exact="pneumonia" post="cases caused by a novel pathogen emerged in Wuhan,"/>
  <result pre="emerged in Wuhan, a city of 11 million people in" exact="Central" post="China. The pathogen was soon identified as the novel"/>
  <result pre="Dorp et al. estimated that the initial timing of human" exact="infection" post="with SARS-CoV-2 may have been in early December or"/>
  <result pre="of SARS-CoV-2 and the place of origin of human SARS-CoV-2" exact="infections" post="remain uncertain, even though Wuhan was the first city"/>
  <result pre="even though Wuhan was the first city in which this" exact="disease" post="was detected and managed. As of March 30, 2020,"/>
  <result pre="Patients in mainland China accounted for over 60% of the" exact="total" post="cases. Interestingly, the average death rate in mainland China"/>
  <result pre="the average death rate in mainland China (approximately 6.5%) was" exact="lower" post="than the worldwide average death rate (9.3%). The higher"/>
  <result pre="rate (9.3%). The higher cure rate in China for SARS" exact="infections" post="was attributed to combining traditional Chinese medicine (TCM) with"/>
  <result pre="to induce the host innate immune response. Lopinavirâ€&quot;ritonavir, the anti-human" exact="immunodeficiency" post="virus (HIV) combination drugs, was shown to be beneficial"/>
  <result pre="demonstrated reduced hospital stays and improved the progression of COVID-19" exact="pneumonia" post="after CQ phosphate treatment with no severe adverse reactions.17"/>
  <result pre="COVID-19. It has been thought that deaths induced by SARS-CoV-2" exact="infection" post="are due to vigorous systemic inflammation caused by â€œcytokine"/>
  <result pre="that deaths induced by SARS-CoV-2 infection are due to vigorous" exact="systemic" post="inflammation caused by â€œcytokine stormsâ€�, driven by proinflammatory cytokines"/>
  <result pre="caused by â€œcytokine stormsâ€�, driven by proinflammatory cytokines such as" exact="tumor" post="necrosis factor-Î± (TNF-Î±), interleukin-1 (IL-1), interleukin-6 (IL-6), and interferon"/>
  <result pre="interleukin 6 (IL-6)-neutralizing activity, has been used to clinically treat" exact="rheumatoid arthritis." post="In a recent initial clinical trial, tocilizumab was used"/>
  <result pre="patients in 2002â€&quot;2003 due to their significant suppression of exaggerated" exact="systemic" post="inflammation induced by SARS-CoV infections. However, high-dose therapy with"/>
  <result pre="SARS-CoV reported in 2002â€&quot;2003,21 including marked improvement of symptoms, shortened" exact="disease" post="course, reduced side effects caused by conventional therapeutics, and"/>
  <result pre="prescriptions were recommended for patients in different phases of the" exact="disease" post="and stages, including medical observation period, clinical treatment period,"/>
  <result pre="of the combined treatment of TCM and Western medicine.24 A" exact="total" post="of 92% of COVID-19 patients in China received TCM"/>
  <result pre="of COVID-19 patients in China received TCM treatment, with a" exact="total" post="effective rate of 90%.25 Among the recommended TCM formulas"/>
  <result pre="among the recruited 80 COVID-19 patients, the average duration of" exact="viral" post="nucleic acid detection was 7 (Â±4) days in the"/>
  <result pre="the safety and efficacy of LHQWC in COVID-19 patients. A" exact="total" post="of 284 patients were randomized to receive standard treatment"/>
  <result pre="discharged, and none of the patients with mild and moderate" exact="disease" post="progressed to the severe stage. Among these patients, out"/>
  <result pre="using liquid chromatography coupled with high-resolution mass spectrometry (HRMS). A" exact="total" post="of 129 compounds were identified or tentatively characterized from"/>
  <result pre="compounds from different herbs in QFPDT may interfere with the" exact="disease" post="process of COVID-19 through multiple signaling pathways, such as"/>
  <result pre="such as Toll-like receptor activation and IFN response induced by" exact="viral infection," post="thereby reducing the secretion of inflammatory cytokines and inhibiting"/>
  <result pre="infection, thereby reducing the secretion of inflammatory cytokines and inhibiting" exact="viral" post="replication to protect patients.25 TCM was established on a"/>
  <result pre="of China14,a clinicalÂ classification criteriaÂ forÂ classification therapeuticÂ regimen Mild" exact="Nonspecific" post="clinical symptoms and no manifestation of pneumonia based on"/>
  <result pre="therapeuticÂ regimen Mild Nonspecific clinical symptoms and no manifestation of" exact="pneumonia" post="based on medical imaging. General treatment: Moderate Fever and"/>
  <result pre="symptoms and no manifestation of pneumonia based on medical imaging." exact="General" post="treatment: Moderate Fever and respiratory tract symptoms, and manifestation"/>
  <result pre="manifestation of pneumonia based on medical imaging. General treatment: Moderate" exact="Fever" post="and respiratory tract symptoms, and manifestation of pneumonia based"/>
  <result pre="pneumonia based on medical imaging. General treatment: Moderate Fever and" exact="respiratory" post="tract symptoms, and manifestation of pneumonia based on medical"/>
  <result pre="treatment: Moderate Fever and respiratory tract symptoms, and manifestation of" exact="pneumonia" post="based on medical imaging. (1)Â StayÂ inÂ bedÂ toÂ"/>
  <result pre="balanced diet and maintain the balance of water and electrolytes." exact="Severe" post="At least one of the following symptoms in adults:"/>
  <result pre="hydrogen and oxygen mixture (H2/O2) of 66.6%/33.3%, if possible. (1)" exact="Respiratory" post="distress, respiration rate (RR) &amp;gt; 30/min; (3) Antiviral therapies:"/>
  <result pre="Chinese medicine (TCM) treatments, shown in Table 2. (3) Arterial" exact="partial" post="pressure of oxygen (PaO2)/oxygen concentration (FiO2) of â‰¤300 mmHg."/>
  <result pre="based on equation of PaO2/FiO2 Ã— (atmospheric pressure (mmHg)/760). (1)" exact="Respiratory" post="support: oxygen inhalation, noninvasive ventilation, invasive ventilation; salvage therapies"/>
  <result pre="(ECMO). Patients with &amp;gt;50% lesions progression within 24â€&quot;48 h in" exact="pulmonary" post="imaging should be treated as severe cases of COVID-19."/>
  <result pre="any of the following: (3) Use of vasoactive drugs. (1)" exact="Respiratory" post="failure occurs and mechanical ventilation is required; (4) Renal"/>
  <result pre="(1) Respiratory failure occurs and mechanical ventilation is required; (4)" exact="Renal" post="replacement therapy for patients with renal failure. (2) Shock;"/>
  <result pre="ventilation is required; (4) Renal replacement therapy for patients with" exact="renal failure." post="(2) Shock; (5) Convalescent-phase plasma therapy. (3) Complicated with"/>
  <result pre="with renal failure. (2) Shock; (5) Convalescent-phase plasma therapy. (3)" exact="Complicated" post="with other organ failure that requires monitoring and treatment"/>
  <result pre="monitoring and treatment in an intensive care unit (ICU). (6)" exact="Blood" post="dialysis. Â (7) Immunotherapy: trastuzumab for patients with a"/>
  <result pre="BID Moderate Fever, cough with less sputum or yellow sputum," exact="chest" post="tightness, and shortness of breath Prescription 3 (also named"/>
  <result pre="and Radix Glycyrrhizae (10 g). One dose per day, BID" exact="Severe" post="Fever,Â flushing,Â cough,Â lessÂ yellowÂ sticky sputum with or"/>
  <result pre="administeredÂ aloneÂ or in combination with Xue Bi Jing injection" exact="Severe" post="fever and polydipsia, anhelation, delirium, blurred vision, hematemesis, epistaxis,"/>
  <result pre="and documented a number of effective compounds. As there are" exact="limited" post="numbers of CoVs and as these CoVs have relatively"/>
  <result pre="1 Chloroquine (CQ) IncreasesÂ endosomalÂ pH; disrupts intracellular trafficking and" exact="viral" post="fusion events; and interferes with glycosylation of cellular receptors"/>
  <result pre="Î¼M; CC50: 261 Î¼M; SI: 30 SARS-CoV Keyaerts et al.37" exact="Mouse" post="model Intranasal administration of CQ (50 mg/kg BW) resulted"/>
  <result pre="CQ (50 mg/kg BW) resulted in a minor reduction in" exact="viral" post="titers in the lung. SARS-CoV Barnard et al.79 A"/>
  <result pre="Yao et al.80 Open-label, controlled clinical trial Significantly associated with" exact="viral" post="load reduction/disappearance in COVID-19 patients. Synergetic effects when used"/>
  <result pre="MahÃ©vas et al.45 3 Remdesivir (RDV) Inhibits RdRp and blocks" exact="viral" post="RNA synthesis; terminates the nonobligate chain. In vitro IC50:"/>
  <result pre="Î¼M; CC50: &amp;gt;10 Î¼M; SI: &amp;gt;167 SARS-CoV Agostini et al.52" exact="Mouse" post="model Ameliorated SARS-CoV-induced weight loss; reduced SARS-CoV-induced lung pathology"/>
  <result pre="model Ameliorated SARS-CoV-induced weight loss; reduced SARS-CoV-induced lung pathology and" exact="viral" post="load in the lungs; and improved clinical signs of"/>
  <result pre="viral load in the lungs; and improved clinical signs of" exact="disease" post="as well as respiratory function. SARS-CoV Sheahan et al.53"/>
  <result pre="lungs; and improved clinical signs of disease as well as" exact="respiratory" post="function. SARS-CoV Sheahan et al.53 Observational, retrospective study Clinical"/>
  <result pre="placebo in shortening the time to recovery in patients with" exact="lower" post="respiratory tract infection. SARS-CoV-2 Beigel et al.56 Double-blind, randomized,"/>
  <result pre="in shortening the time to recovery in patients with lower" exact="respiratory" post="tract infection. SARS-CoV-2 Beigel et al.56 Double-blind, randomized, controlled"/>
  <result pre="Wang et al.57 4 Favipiravir (FPV) Inhibits RdRp and blocks" exact="viral" post="RNA synthesis. In vitro IC50: 61.8 Î¼M; CC50: &amp;gt;400"/>
  <result pre="et al.16 Open-label, controlled clinical trial Significant shorter time to" exact="viral" post="clearance and improvement in chest imaging compared with lopinavir/ritonavir,"/>
  <result pre="trial Significant shorter time to viral clearance and improvement in" exact="chest" post="imaging compared with lopinavir/ritonavir, another antiviral drug. Cai et"/>
  <result pre="pyrexia and cough. SARS-CoV-2 Chen et al.64 5 Ribavirin Inhibits" exact="viral" post="RNA synthesis and mRNA capping. In vitro The cytopathic"/>
  <result pre="al.16 6 Lopinavir Inhibits 3CLpro and blocks the cleavage of" exact="viral" post="peptides into functional units. In vitro The cytopathic effect"/>
  <result pre="Regulates immunity function and inhibits the release of inflammatory factors." exact="Mouse" post="model Intraperitoneal injection of matrine sodium chloride significantly improved"/>
  <result pre="al.1 IC50: 0.47 Î¼M; CC: 3.81 Î¼M; SI: 8.11 HCoV-NL63" exact="Mouse" post="model Intraperitoneal injection at 15 mg/kg provided an 83.3%"/>
  <result pre="with an EC50 of 1 Î¼M. SARS-CoV-2 Hoffmann et al.78" exact="Mouse" post="model Protected mice against SARS-CoV lethal infection with a"/>
  <result pre="Hoffmann et al.78 Mouse model Protected mice against SARS-CoV lethal" exact="infection" post="with a survival rate of 60%. SARS-CoV Zhou et"/>
  <result pre="5.9 Park et al.107 34 Isobavachalcone Psoralea corylifolia 7.3 4.9" exact="Mixed" post="Kim et al.108 35 Psoralidin 4.2 1.7 36 Terrestrimine"/>
  <result pre="35 Psoralidin 4.2 1.7 36 Terrestrimine Tribulus terrestris 15.8 10" exact="Mixed" post="Song et al.109 aNM, not mentioned; NT, not tested."/>
  <result pre="higher affinity than that of the substrate to the protease." exact="Mixed" post="inhibition, an inhibitor molecule binds at an allosteric site"/>
  <result pre="Among all seven tested drugs, CQ/HCQ and RDV potently blocked" exact="viral infection" post="at low micromolar concentrations in cell cultures and showed"/>
  <result pre="all seven tested drugs, CQ/HCQ and RDV potently blocked viral" exact="infection" post="at low micromolar concentrations in cell cultures and showed"/>
  <result pre="CQ and HCQ CQ (1), a widely used antimalarial and" exact="autoimmune" post="inhibitory drug, was reported to be a potential broad-spectrum"/>
  <result pre="vitro in Vero E6 cells. CQ was able to block" exact="viral" post="replication at a low concentration [effective concentration for 50%"/>
  <result pre="the clinical effects of CQ on SARS-CoV-2, in which a" exact="total" post="of 197 patients from 12 hospitals in Guangdong and"/>
  <result pre="patients were included as historical controls. The median time for" exact="viral" post="RNA to be undetectable and the duration of fever"/>
  <result pre="in France and suggested that 600 mg/day HCQ significantly reduced" exact="viral" post="loads in these patients. They also showed that when"/>
  <result pre="of HCQ and showed that HCQ treatment significantly shortened the" exact="disease" post="course.42 However, the effectiveness of HCQ for treating COVID-19"/>
  <result pre="It is an adenosine analog that is incorporated into nascent" exact="viral" post="RNA chains, leading to premature termination.50 A recent study"/>
  <result pre="0.77 Î¼M, respectively. The time-of-addition assay confirmed that RDV affects" exact="viral" post="replication postviral entry, supporting its mode of action as"/>
  <result pre="Î¼M, respectively.51 Additionally, it potently inhibited SARS-CoV in human airway" exact="epithelial" post="(HAE) cells with an IC50 of 0.06 Î¼M and"/>
  <result pre="prophylactic or early therapeutic administration of RDV significantly reduced lung" exact="viral" post="loads and improved clinical outcomes in a murine infection"/>
  <result pre="lung viral loads and improved clinical outcomes in a murine" exact="infection" post="model.53 Holshue and colleagues reported the first patient diagnosed"/>
  <result pre="was compassionately treated with intravenous RDV for the progression of" exact="pneumonia" post="on day 7 of hospitalization (illness day 11). Encouragingly,"/>
  <result pre="in 36 of 53 patients (68%).55 In another study, a" exact="total" post="of 1063 hospitalized COVID-19 patients were included in a"/>
  <result pre="RDV treatment could shorten the recovery time in hospitalized COVID-19" exact="adult" post="patients with lower respiratory tract infection.56 However, Wang and"/>
  <result pre="shorten the recovery time in hospitalized COVID-19 adult patients with" exact="lower" post="respiratory tract infection.56 However, Wang and collaborators recently reported"/>
  <result pre="the recovery time in hospitalized COVID-19 adult patients with lower" exact="respiratory" post="tract infection.56 However, Wang and collaborators recently reported another"/>
  <result pre="and collaborators recently reported another study on hospitalized severe COVID-19" exact="adult" post="patients, in which RDV did not yield significant clinical"/>
  <result pre="RNA polymerase (RdRp) of RNA viruses such as influenza, Ebola," exact="yellow fever," post="chikungunya, norovirus and enterovirus.58,59 FPV is converted into an"/>
  <result pre="in cells that is recognized as a substrate by the" exact="viral" post="RNA polymerase, thus inhibiting RNA polymerase activity.60 A recent"/>
  <result pre="lopinavir/ritonavir plus IFN-Î± as an inhaled aerosol. A significantly shorter" exact="viral" post="clearance time was observed in the FPV group than"/>
  <result pre="day 7. The FPV group also showed significant improvement in" exact="chest" post="imaging compared with the lopinavir/ritonavir group, with an improvement"/>
  <result pre="al. conducted a prospective, randomized, controlled, open-label multicenter trial involving" exact="adult" post="patients with COVID-19. A total of 240 enrolled COVID-19"/>
  <result pre="controlled, open-label multicenter trial involving adult patients with COVID-19. A" exact="total" post="of 240 enrolled COVID-19 patients were randomly assigned to"/>
  <result pre="patients in each group), a broad-spectrum antiviral compound that blocks" exact="viral" post="fusion,63 for 10 days. The results showed that FPV"/>
  <result pre="CoV Inhibitors Another guanine derivative, ribavirin (4), approved for treating" exact="hepatitis C" post="virus (HCV) and respiratory syncytial virus (RSV) infections clinically,"/>
  <result pre="ribavirin (4), approved for treating hepatitis C virus (HCV) and" exact="respiratory" post="syncytial virus (RSV) infections clinically, has been evaluated in"/>
  <result pre="treating hepatitis C virus (HCV) and respiratory syncytial virus (RSV)" exact="infections" post="clinically, has been evaluated in SARS and MERS patients,"/>
  <result pre="in SARS and MERS patients, but side effects such as" exact="anemia" post="can be severe at high doses,65 and whether it"/>
  <result pre="the therapeutic effect of matrine sodium chloride in a mouse" exact="pneumonia" post="model infected with HCoV-229E. The results showed that intraperitoneal"/>
  <result pre="and CD8+ T cells, the number of B cells in" exact="peripheral" post="blood, the production of IL-6, IL-10, TNF-Î±, IFN-Î³, and"/>
  <result pre="blood, the production of IL-6, IL-10, TNF-Î±, IFN-Î³, and the" exact="viral" post="load in the lung were significantly inhibited compared to"/>
  <result pre="(8), isolated from Amaryllidaceae plants, has been reported to inhibit" exact="poliomyelitis" post="virus, Bunyamwera virus, herpes simplex virus, dengue virus, West"/>
  <result pre="plants, has been reported to inhibit poliomyelitis virus, Bunyamwera virus," exact="herpes" post="simplex virus, dengue virus, West Nile virus, and SARS-CoV"/>
  <result pre="they found that lycorine protected BALB/c mice against lethal HCoV-OC43" exact="infection" post="by suppressing viral replication in the central nervous system."/>
  <result pre="lycorine protected BALB/c mice against lethal HCoV-OC43 infection by suppressing" exact="viral" post="replication in the central nervous system. Twenty days after"/>
  <result pre="against lethal HCoV-OC43 infection by suppressing viral replication in the" exact="central nervous system." post="Twenty days after HCoV-OC43 infection, intraperitoneal injection of lycorine"/>
  <result pre="that lycorine could be a broad-spectrum antiviral agent against CoV" exact="infection" post="and might offer promising therapeutic possibilities for combating SARS-CoV-2"/>
  <result pre="Camostat (9) is a serine protease inhibitor used to treat" exact="chronic" post="pancreatitis. Zhou et al. reported that camostat was effective"/>
  <result pre="that camostat was effective in protecting mice from a lethal" exact="infection" post="by SARS-CoV, with a survival rate of 60%.77 Recently,"/>
  <result pre="flavonoid classes were identified as effective SARS-CoV inhibitors by targeting" exact="viral" post="proteinases.87,88 Figure 2 Genome structures of SARS-CoV- 2 and"/>
  <result pre="shown in boxes. (Bottom panel) A schematic representation of the" exact="morphology" post="of the SARS-CoV-2 virus. The virus is a large"/>
  <result pre="3 Candidate antiviral agents for SARS-CoV-2 in relation to the" exact="viral" post="replication cycle. SARS-CoV-2 enters host cells either through an"/>
  <result pre="binding to the host cell receptor angiotensin-converting enzyme 2 (ACE2)." exact="Viral" post="genomic RNA is unveiled in the cytoplasm, and the"/>
  <result pre="and the single-stranded positive-sense genome is transcribed to produce the" exact="viral" post="proteases papain-like protease (PLpro) and 3C-like serine protease (3CLpro),"/>
  <result pre="and Hel proteins are gathered into replicationâ€&quot;transcription complexes (RTCs) for" exact="viral" post="replication and transcription. RTCs synthesize negative-strand guide RNA (gRNA)"/>
  <result pre="guide RNA (gRNA) and a set of subgenomic RNAs for" exact="viral" post="replication and transcription. The newly produced subgenomic RNAs are"/>
  <result pre="and transcription. The newly produced subgenomic RNAs are translated into" exact="viral" post="structural proteins such as the S, membrane (M), and"/>
  <result pre="rough endoplasmic reticulum (ER) and then transported to the ER-Golgi" exact="intermediate" post="compartment (ERGIC) to assemble with the N protein-encapsidated RNA"/>
  <result pre="(ERGIC) to assemble with the N protein-encapsidated RNA to form" exact="viral" post="particles. Virions are then released from the cell through"/>
  <result pre="main protease because it plays a pivotal role in processing" exact="viral" post="polyproteins and controlling replicase complex activity.91 Research on drugging"/>
  <result pre="PLpro inhibitory activity (IC50 = 7.1 and 1.2 Î¼M, respectively)." exact="Protein" post="inhibitor analysis showed that chalcones exhibited competitive inhibition of"/>
  <result pre="Inhibitors Recent studies directed at PLpro suggested potential roles beyond" exact="viral" post="peptide cleavage, including deISGylation, deubiquitination, and involvement in evasion"/>
  <result pre="is also an attractive target, as it is indispensable for" exact="viral" post="replication.110 Hel has been reported to possess the ability"/>
  <result pre="endosomal (acidic) compartments where the target cysteine proteases required for" exact="viral" post="entry are located.77 Thus, vinyl sulfones are promising antiviral"/>
  <result pre="Î¼M. However, the nucleoside analog penciclovir (50) was required for" exact="viral" post="inhibition, yielding an EC50 of 95.96 Î¼M. Further in"/>
  <result pre="Further in vivo studies of the two drugs against SARS-CoV-2" exact="infection" post="are recommended.16 3.2.5 Inhibitors with Undefined Replication Inhibiting Mechanisms"/>
  <result pre="is currently used to treat patients infected with HCV and" exact="upper" post="respiratory tract infections.117 Cinatl et al. examined the antiviral"/>
  <result pre="currently used to treat patients infected with HCV and upper" exact="respiratory" post="tract infections.117 Cinatl et al. examined the antiviral effects"/>
  <result pre="the 15 derivatives tested, seven inhibited SARS-CoV replication at concentrations" exact="lower" post="than GL. Addition of N-acetylglucosamine into the GL glycoside"/>
  <result pre="which might be important for the interaction of GL with" exact="viral" post="proteins, especially the highly glycosylated S protein on the"/>
  <result pre="on the virus envelope. The S protein is important for" exact="viral" post="entry into the cell by binding to cellular receptors.119"/>
  <result pre="cell by binding to cellular receptors.119 It is speculated that" exact="viral" post="entry was inhibited by N-acetylglucosamine binding to the carbohydrates"/>
  <result pre="are effective against viruses such as HIV, influenza virus, and" exact="herpes" post="simplex virus.121 Cheng et al. evaluated the antiviral activity"/>
  <result pre="1.7 Î¼M. Time-of-addition studies showed that SSb (55) interferes with" exact="viral" post="replication early during the viral replication cycle, likely due"/>
  <result pre="that SSb (55) interferes with viral replication early during the" exact="viral" post="replication cycle, likely due to absorption and penetration of"/>
  <result pre="HCoV-OC43 than the other two alkaloids. Tetrandrine appeared to inhibit" exact="viral" post="replication during the early infection stage, likely related to"/>
  <result pre="alkaloids. Tetrandrine appeared to inhibit viral replication during the early" exact="infection" post="stage, likely related to interaction with the viral S"/>
  <result pre="the early infection stage, likely related to interaction with the" exact="viral" post="S and N proteins.122 A SARS-CoV and Vero E6"/>
  <result pre="ranging from 35 to 365 Î¼M, their cytotoxicity was much" exact="lower" post="with CC50 values ranging from 1462 to 24â€¯000 Î¼M."/>
  <result pre="are inconsistencies in the origins of the herbs used and" exact="incomplete" post="understandings of the active compounds in these preparations and"/>
  <result pre="evaluating the efficacy of TCMs in the treatment of SARS-CoV" exact="infections" post="were found to be poorly designed. Hopefully, current and"/>
  <result pre="COVID-19 are still urgently needed. Various stages of the SARS-CoV-2" exact="viral" post="life cycle could be targeted by small molecule antiviral"/>
  <result pre="cycle could be targeted by small molecule antiviral inhibitors. Four" exact="viral" post="NSPs, including protease 3CLpro, PLpro, RdRp, and Hel play"/>
  <result pre="a replication-deficient adenovirus (Ad5-hACE2). These mice showed weight loss, severe" exact="pulmonary" post="pathology, and high viral load in the lungs post-SARS-CoV-2"/>
  <result pre="These mice showed weight loss, severe pulmonary pathology, and high" exact="viral" post="load in the lungs post-SARS-CoV-2 infection but no mortality.127"/>
  <result pre="pulmonary pathology, and high viral load in the lungs post-SARS-CoV-2" exact="infection" post="but no mortality.127 Therefore, the limited availability of animal"/>
  <result pre="in the lungs post-SARS-CoV-2 infection but no mortality.127 Therefore, the" exact="limited" post="availability of animal models remains an obstacle65 Due to"/>
  <result pre="availability of animal models remains an obstacle65 Due to the" exact="acute" post="nature of COVID-19 and the importance of immunopathology, combination"/>
  <result pre="did not benefit hospitalized COVID-19 patients who did not require" exact="respiratory" post="support.130 However, the use of glucocorticoids might cause side"/>
  <result pre="interests are focused on detections and small-molecule targeted interventions for" exact="respiratory" post="diseases. Dan Xu received her Ph.D. in Cell Biology"/>
  <result pre="Zanin is a professor at the State Key Laboratory of" exact="Respiratory" post="Diseases, Guangzhou, and the School of Public Health, The"/>
  <result pre="Zifeng Yang is a professor at State Key Laboratory of" exact="Respiratory" post="Diseases, the First Affiliated Hospital of Guangzhou Medical University"/>
  <result pre="He is a clinician scientist with particular interest in emerging" exact="viral" post="diseases at the animalâ€&quot;human interface, including avian H7N9 and"/>
  <result pre="H5N6 influenza virus and MERS-CoV, as well as the associated" exact="viral" post="immunology. His research interests also involve the use of"/>
  <result pre="underlying mechanisms of approved drugs, novel compounds, and TCMs against" exact="respiratory" post="viruses. Jianxin Chen is a professor at College of"/>
  <result pre="and natural products against influenza viruses and porcine reproductive and" exact="respiratory" post="syndrome viruses (PRRSV). Acknowledgments We thank Prof. Jincun Zhao"/>
  <result pre="natural products against influenza viruses and porcine reproductive and respiratory" exact="syndrome" post="viruses (PRRSV). Acknowledgments We thank Prof. Jincun Zhao from"/>
  <result pre="house mouse CC50 50% cytotoxic concentration CoV coronavirus COVID-19 coronavirus" exact="disease" post="2019 CPE cytopathogenic effect CVB3 coxsackievirus B3 GL glycyrrhizic"/>
  <result pre="CVB3 coxsackievirus B3 GL glycyrrhizic acid (glycyrrhizin) HAE human airway" exact="epithelial" post="HCoV-229E human coronavirus 229E GFP green fluorescent protein HCoV-HKU1"/>
  <result pre="Jinhua Qinggan granule LHQWC Lianhua Qingwen capsule MERS-CoV Middle East" exact="respiratory" post="syndrome coronavirus NHC National Health Commission NSP nonstructural protein"/>
  <result pre="Qinggan granule LHQWC Lianhua Qingwen capsule MERS-CoV Middle East respiratory" exact="syndrome" post="coronavirus NHC National Health Commission NSP nonstructural protein NTPase/Hel"/>
  <result pre="RdRp RNA-dependent RNA polymerase NTPase RNA nucleoside triphosphatase SARS-CoV severe" exact="acute" post="respiratory syndrome coronavirus SI selective index TCM traditional Chinese"/>
  <result pre="RNA-dependent RNA polymerase NTPase RNA nucleoside triphosphatase SARS-CoV severe acute" exact="respiratory" post="syndrome coronavirus SI selective index TCM traditional Chinese medicine"/>
  <result pre="RNA polymerase NTPase RNA nucleoside triphosphatase SARS-CoV severe acute respiratory" exact="syndrome" post="coronavirus SI selective index TCM traditional Chinese medicine TMPRSS2"/>
  <result pre="LiD. X.; YuenK. Y.; Peiris; GuanY.Epidemiology and cause of severe" exact="acute" post="respiratory syndrome (SARS) in Guangdong, Peopleâ€™s Republic of China,"/>
  <result pre="X.; YuenK. Y.; Peiris; GuanY.Epidemiology and cause of severe acute" exact="respiratory" post="syndrome (SARS) in Guangdong, Peopleâ€™s Republic of China, in"/>
  <result pre="YuenK. Y.; Peiris; GuanY.Epidemiology and cause of severe acute respiratory" exact="syndrome" post="(SARS) in Guangdong, Peopleâ€™s Republic of China, in February,"/>
  <result pre="W.; BelliniW. J.; AndersonL. J.A novel coronavirus associated with severe" exact="acute" post="respiratory syndrome. N. Engl. J. Med.2003, 348, 1953â€&quot;1966. 10.1056/NEJMoa030781.12690092"/>
  <result pre="BelliniW. J.; AndersonL. J.A novel coronavirus associated with severe acute" exact="respiratory" post="syndrome. N. Engl. J. Med.2003, 348, 1953â€&quot;1966. 10.1056/NEJMoa030781.12690092 DrostenC.;"/>
  <result pre="DoerrH. W.Identification of a novel coronavirus in patients with severe" exact="acute" post="respiratory syndrome. N. Engl. J. Med.2003, 348, 1967â€&quot;1976. 10.1056/NEJMoa030747.12690091"/>
  <result pre="W.Identification of a novel coronavirus in patients with severe acute" exact="respiratory" post="syndrome. N. Engl. J. Med.2003, 348, 1967â€&quot;1976. 10.1056/NEJMoa030747.12690091 Revised"/>
  <result pre="Med.2003, 348, 1967â€&quot;1976. 10.1056/NEJMoa030747.12690091 Revised U.S. Surveillance Case Definition for" exact="Severe" post="Acute Respiratory Syndrome (SARS) and Update on SARS Casesâ€&quot;United"/>
  <result pre="348, 1967â€&quot;1976. 10.1056/NEJMoa030747.12690091 Revised U.S. Surveillance Case Definition for Severe" exact="Acute" post="Respiratory Syndrome (SARS) and Update on SARS Casesâ€&quot;United States"/>
  <result pre="1967â€&quot;1976. 10.1056/NEJMoa030747.12690091 Revised U.S. Surveillance Case Definition for Severe Acute" exact="Respiratory" post="Syndrome (SARS) and Update on SARS Casesâ€&quot;United States and"/>
  <result pre="10.1056/NEJMoa030747.12690091 Revised U.S. Surveillance Case Definition for Severe Acute Respiratory" exact="Syndrome" post="(SARS) and Update on SARS Casesâ€&quot;United States and Worldwide,"/>
  <result pre="https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5249a2.htm (accessed Jun 29, 2020). World Health Organization. Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV). 11 March 2019. https://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-(mers-cov) (accessed Jun"/>
  <result pre="(accessed Jun 29, 2020). World Health Organization. Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV). 11 March 2019. https://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-(mers-cov) (accessed Jun 29,"/>
  <result pre="LiuL. L.; YanB.; ZhanF.-X.; WangY. Y.; XiaoG. F.; ShiZ. L.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="BoshierF. A. T.; OrtizA. T.; BallouxF.Emergence of genomic diversity and" exact="recurrent" post="mutations in SARS-CoV-2. Infect., Genet. Evol.2020, 83, 10435110.1016/j.meegid.2020.104351.32387564 World"/>
  <result pre="SARS-CoV-2. Infect., Genet. Evol.2020, 83, 10435110.1016/j.meegid.2020.104351.32387564 World Health Organization. Coronavirus" exact="Disease" post="(COVID-19) Pandemic. Augest 14, 2020, https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed Aug 14,"/>
  <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019-nCoV. ChemBioChem2020, 21, 730â€&quot;738. 10.1002/cbic.202000047.32022370"/>
  <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019-nCoV. ChemBioChem2020, 21, 730â€&quot;738. 10.1002/cbic.202000047.32022370 JiaW.;"/>
  <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019-nCoV. ChemBioChem2020, 21, 730â€&quot;738. 10.1002/cbic.202000047.32022370 JiaW.; GaoW.Is"/>
  <result pre="of Traditional Chinese Medicine of the PRC. Guidance for Corona" exact="Virus Disease" post="2019: Prevention, Control, Diagnosis and Management; Peopleâ€™s Medical Publishing"/>
  <result pre="Traditional Chinese Medicine of the PRC. Guidance for Corona Virus" exact="Disease" post="2019: Prevention, Control, Diagnosis and Management; Peopleâ€™s Medical Publishing"/>
  <result pre="Y.Treatment with Lopinavir/Ritonavir or interferon- Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmoset. J."/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studies. BioSci. Trends2020, 14, 72â€&quot;73. 10.5582/bst.2020.01047.32074550 LaiS."/>
  <result pre="studies. BioSci. Trends2020, 14, 72â€&quot;73. 10.5582/bst.2020.01047.32074550 LaiS. T.Treatment of severe" exact="acute" post="respiratory syndrome. Eur. J. Clin. Microbiol. Infect. Dis.2005, 24,"/>
  <result pre="BioSci. Trends2020, 14, 72â€&quot;73. 10.5582/bst.2020.01047.32074550 LaiS. T.Treatment of severe acute" exact="respiratory" post="syndrome. Eur. J. Clin. Microbiol. Infect. Dis.2005, 24, 583â€&quot;591."/>
  <result pre="10.1101/2020.03.30.20048058. XieL.; LiuY.; XiaoY.; TianQ.; FanB.; ZhaoH.; ChenW.Follow-up study on" exact="pulmonary" post="function and lung radiographic changes in rehabilitating severe acute"/>
  <result pre="on pulmonary function and lung radiographic changes in rehabilitating severe" exact="acute" post="respiratory syndrome patients after discharge. Chest2005, 127, 2119â€&quot;2124. 10.1378/chest.127.6.2119.15947329"/>
  <result pre="pulmonary function and lung radiographic changes in rehabilitating severe acute" exact="respiratory" post="syndrome patients after discharge. Chest2005, 127, 2119â€&quot;2124. 10.1378/chest.127.6.2119.15947329 TongX.;"/>
  <result pre="function and lung radiographic changes in rehabilitating severe acute respiratory" exact="syndrome" post="patients after discharge. Chest2005, 127, 2119â€&quot;2124. 10.1378/chest.127.6.2119.15947329 TongX.; LiA.;"/>
  <result pre="ShiX.; LiP.; TianX.; LinF.; CaoY.; JinL.; ChangM.; WangY.TCM treatment of" exact="infectious" post="atypical pneumonia--a report of 16 cases. J. Tradit. Chin."/>
  <result pre="LiP.; TianX.; LinF.; CaoY.; JinL.; ChangM.; WangY.TCM treatment of infectious" exact="atypical" post="pneumonia--a report of 16 cases. J. Tradit. Chin. Med.2004,"/>
  <result pre="P.; KangY. K.Chinese herbs combined with western medicine for severe" exact="acute" post="respiratory syndrome (SARS). Cochrane Database Syst. Rev.2006, 10.1002/14651858.CD004882.pub2. ZhangM."/>
  <result pre="KangY. K.Chinese herbs combined with western medicine for severe acute" exact="respiratory" post="syndrome (SARS). Cochrane Database Syst. Rev.2006, 10.1002/14651858.CD004882.pub2. ZhangM. M.;"/>
  <result pre="K.Chinese herbs combined with western medicine for severe acute respiratory" exact="syndrome" post="(SARS). Cochrane Database Syst. Rev.2006, 10.1002/14651858.CD004882.pub2. ZhangM. M.; LiuX."/>
  <result pre="Paidu decoction and Ma Xing Shi Gan decoction against coronavirus" exact="disease" post="2019 (COVID-19): In Silico and Experimental Study. Pharmacol. Res.2020,"/>
  <result pre="ZengY.; LiT.; WangX.Effect of Jinhua Qinggan granules on novel coronavirus" exact="pneumonia" post="in patients. J. Tradit. Chin. Med.2020, 40, 467â€&quot;472. 10.19852/j.cnki.jtcm.2020.03.016.32506862"/>
  <result pre="Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus" exact="disease" post="2019: a multicenter, prospective, randomized controlled trial. Phytomedicine2020, 15324210.1016/j.phymed.2020.153242.32425361"/>
  <result pre="WeiY.; JinN.; JiangC.Anti-malaria drug chloroquine is highly effective in treating" exact="avian influenza" post="A H5N1 virus infection in an animal model. Cell"/>
  <result pre="chloroquine is highly effective in treating avian influenza A H5N1" exact="virus infection" post="in an animal model. Cell Res.2013, 23, 300â€&quot;302. 10.1038/cr.2012.165.23208422"/>
  <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal model. Cell Res.2013, 23, 300â€&quot;302. 10.1038/cr.2012.165.23208422"/>
  <result pre="FDA-approved compound library identifies four small-molecule inhibitors of middle east" exact="respiratory" post="syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother.2014,"/>
  <result pre="compound library identifies four small-molecule inhibitors of middle east respiratory" exact="syndrome" post="coronavirus replication in cell culture. Antimicrob. Agents Chemother.2014, 58,"/>
  <result pre="KeyaertsE.; VijgenL.; MaesP.; NeytsJ.; Van RanstM.In vitro inhibition of severe" exact="acute" post="respiratory syndrome coronavirus by chloroquine. Biochem. Biophys. Res. Commun.2004,"/>
  <result pre="VijgenL.; MaesP.; NeytsJ.; Van RanstM.In vitro inhibition of severe acute" exact="respiratory" post="syndrome coronavirus by chloroquine. Biochem. Biophys. Res. Commun.2004, 323,"/>
  <result pre="MaesP.; NeytsJ.; Van RanstM.In vitro inhibition of severe acute respiratory" exact="syndrome" post="coronavirus by chloroquine. Biochem. Biophys. Res. Commun.2004, 323, 264â€&quot;268."/>
  <result pre="Van RanstM.; MaesP.Antiviral activity of chloroquine against human coronavirus OC43" exact="infection" post="in newborn mice. Antimicrob. Agents Chemother.2009, 53, 3416â€&quot;3421. 10.1128/AAC.01509-08.19506054"/>
  <result pre="ShiG.; XieQ.Hydroxychloroquine in patients with mainly mild to moderate coronavirus" exact="disease" post="2019: open label, randomised controlled trial. BMJ.2020, 369, m184910.1136/bmj.m1849.32409561"/>
  <result pre="GodeauB.; GallienS.; Costedoat-ChalumeauN.Clinical efficacy of hydroxychloroquine in patients with Covid-19" exact="pneumonia" post="who require oxygen: observational comparative study using routine care"/>
  <result pre="CihlarT.; SiegelD.; MackmanR. L.; ClarkeM. O.; BaricR. S.; DenisonM. R.Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
  <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonuclease. mBio2018, 9, e00221-1810.1128/mBio.00221-18.29511076 SheahanT."/>
  <result pre="14, 3962â€&quot;3968. 10.1002/asia.201900841.31389664 DongL.; HuS.; GaoJ.Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19). Drug Discoveries Ther.2020, 14, 58â€&quot;60. 10.5582/ddt.2020.01012. FurutaY.;"/>
  <result pre="B.; TakahashiK.; ShirakiK.; SmeeD. F.; BarnardD. L.Favipiravir (T-705), a novel" exact="viral" post="RNA polymerase inhibitor. Antiviral Res.2013, 100, 446â€&quot;454. 10.1016/j.antiviral.2013.09.015.24084488 OestereichL.;"/>
  <result pre="OestereichL.; LÃ¼dtkeA.; WurrS.; RiegerT.; MuÃ±oz-FontelaC.; GÃ¼ntherS.Successful treatment of advanced ebola" exact="virus infection" post="with T-705 (Favipiravir) in a small animal model. Antiviral"/>
  <result pre="LÃ¼dtkeA.; WurrS.; RiegerT.; MuÃ±oz-FontelaC.; GÃ¼ntherS.Successful treatment of advanced ebola virus" exact="infection" post="with T-705 (Favipiravir) in a small animal model. Antiviral"/>
  <result pre="BoriskinY.; LenevaI.; PecheurE.-I.; PolyakS.Arbidol: a broad-spectrum antiviral compound that blocks" exact="viral" post="fusion. Curr. Med. Chem.2008, 15, 997â€&quot;1005. 10.2174/092986708784049658.18393857 ChenC.; ZhangY.;"/>
  <result pre="M.; ChenS. T.; LiangP. H.; WongC. H.Small molecules targeting severe" exact="acute" post="respiratory syndrome human coronavirus. Proc. Natl. Acad. Sci. U."/>
  <result pre="ChenS. T.; LiangP. H.; WongC. H.Small molecules targeting severe acute" exact="respiratory" post="syndrome human coronavirus. Proc. Natl. Acad. Sci. U. S."/>
  <result pre="T.; LiangP. H.; WongC. H.Small molecules targeting severe acute respiratory" exact="syndrome" post="human coronavirus. Proc. Natl. Acad. Sci. U. S. A.2004,"/>
  <result pre="activity in porcine alveolar macrophages co-infected by porcine reproductive and" exact="respiratory" post="syndrome virus and porcine circovirus type 2. Sci. Rep.2016,"/>
  <result pre="in porcine alveolar macrophages co-infected by porcine reproductive and respiratory" exact="syndrome" post="virus and porcine circovirus type 2. Sci. Rep.2016, 6,"/>
  <result pre="by porcine reproductive and respiratory syndrome virus and porcine circovirus" exact="type 2." post="Sci. Rep.2016, 6, 2440110.1038/srep24401.27080155 PanQ. M.; LiY. H.; HuaJ.;"/>
  <result pre="of matrine sodium chloride injection on a mouse model combining" exact="disease" post="with syndrome of human coronavirus pneumonia with cold-dampness pestilence"/>
  <result pre="sodium chloride injection on a mouse model combining disease with" exact="syndrome" post="of human coronavirus pneumonia with cold-dampness pestilence attacking the"/>
  <result pre="a mouse model combining disease with syndrome of human coronavirus" exact="pneumonia" post="with cold-dampness pestilence attacking the lung. Acta Pharm. Sin.2020,"/>
  <result pre="combining disease with syndrome of human coronavirus pneumonia with cold-dampness" exact="pestilence" post="attacking the lung. Acta Pharm. Sin.2020, 55, 366â€&quot;373. HwangY."/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis.2020, 71,"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis.2020, 71, 73210.1093/cid/ciaa237.32150618"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis.2020, 71, 73210.1093/cid/ciaa237.32150618 VlietinckA."/>
  <result pre="10.1016/j.virusres.2007.02.017.17397959 KeumY.; JeongY.Development of chemical inhibitors of the SARS coronavirus:" exact="viral" post="helicase as a potential target. Biochem. Pharmacol.2012, 84, 1351â€&quot;1358."/>
  <result pre="plant terpenoids and lignoids possess potent antiviral activities against severe" exact="acute" post="respiratory syndrome coronavirus. J. Med. Chem.2007, 50, 4087â€&quot;4095. 10.1021/jm070295s.17663539"/>
  <result pre="terpenoids and lignoids possess potent antiviral activities against severe acute" exact="respiratory" post="syndrome coronavirus. J. Med. Chem.2007, 50, 4087â€&quot;4095. 10.1021/jm070295s.17663539 StadlerK.;"/>
  <result pre="and lignoids possess potent antiviral activities against severe acute respiratory" exact="syndrome" post="coronavirus. J. Med. Chem.2007, 50, 4087â€&quot;4095. 10.1021/jm070295s.17663539 StadlerK.; MasignaniV.;"/>
  <result pre="3730â€&quot;3737. 10.1016/j.bmc.2013.04.026.23647823 ZakaryanH.; ArabyanE.; OoA.; ZandiK.Flavonoids: promising natural compounds against" exact="viral" post="infections. Arch. Virol.2017, 162, 2539â€&quot;2551. 10.1007/s00705-017-3417-y.28547385 RyuY. B.; JeongH."/>
  <result pre="ChenJ.-L.; WuY.-T.; WongC.-H.Discovery of potent anilide inhibitors against the severe" exact="acute" post="respiratory syndrome 3CL protease. J. Med. Chem.2005, 48, 4469â€&quot;4473."/>
  <result pre="WuY.-T.; WongC.-H.Discovery of potent anilide inhibitors against the severe acute" exact="respiratory" post="syndrome 3CL protease. J. Med. Chem.2005, 48, 4469â€&quot;4473. 10.1021/jm050184y.15974598"/>
  <result pre="WongC.-H.Discovery of potent anilide inhibitors against the severe acute respiratory" exact="syndrome" post="3CL protease. J. Med. Chem.2005, 48, 4469â€&quot;4473. 10.1021/jm050184y.15974598 KumarV.;"/>
  <result pre="F.; KimM.; LiangP. H.Identification and evaluation of potent middle east" exact="respiratory" post="syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res.2017, 141, 101â€&quot;106."/>
  <result pre="KimM.; LiangP. H.Identification and evaluation of potent middle east respiratory" exact="syndrome" post="coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res.2017, 141, 101â€&quot;106. 10.1016/j.antiviral.2017.02.007.28216367"/>
  <result pre="S.; SantarsieroB. D.; BarrettoN.; BakerS. C.; StevensR. C.; MesecarA. D.Severe" exact="acute" post="respiratory syndrome coronavirus papain-like-protease: structure of a viral deubiquitinating"/>
  <result pre="SantarsieroB. D.; BarrettoN.; BakerS. C.; StevensR. C.; MesecarA. D.Severe acute" exact="respiratory" post="syndrome coronavirus papain-like-protease: structure of a viral deubiquitinating enzyme."/>
  <result pre="D.; BarrettoN.; BakerS. C.; StevensR. C.; MesecarA. D.Severe acute respiratory" exact="syndrome" post="coronavirus papain-like-protease: structure of a viral deubiquitinating enzyme. Proc."/>
  <result pre="MesecarA. D.Severe acute respiratory syndrome coronavirus papain-like-protease: structure of a" exact="viral" post="deubiquitinating enzyme. Proc. Natl. Acad. Sci. U. S. A.2006,"/>
  <result pre="innate immunity by the papain-like protease domain of the severe" exact="acute" post="respiratory syndrome coronavirus. J. Biol. Chem.2007, 282, 32208â€&quot;32221. 10.1074/jbc.M704870200.17761676"/>
  <result pre="immunity by the papain-like protease domain of the severe acute" exact="respiratory" post="syndrome coronavirus. J. Biol. Chem.2007, 282, 32208â€&quot;32221. 10.1074/jbc.M704870200.17761676 ParkJ.;"/>
  <result pre="by the papain-like protease domain of the severe acute respiratory" exact="syndrome" post="coronavirus. J. Biol. Chem.2007, 282, 32208â€&quot;32221. 10.1074/jbc.M704870200.17761676 ParkJ.; JeongJ.;"/>
  <result pre="B.Hirsutenone diarylheptanoids from Alnus Japonica inhibit papain-like protease of severe" exact="acute" post="respiratory syndrome coronavirus. Biol. Pharm. Bull.2012, 35, 2036â€&quot;2042. 10.1248/bpb.b12-00623.22971649"/>
  <result pre="diarylheptanoids from Alnus Japonica inhibit papain-like protease of severe acute" exact="respiratory" post="syndrome coronavirus. Biol. Pharm. Bull.2012, 35, 2036â€&quot;2042. 10.1248/bpb.b12-00623.22971649 ParkJ.-Y.;"/>
  <result pre="from Alnus Japonica inhibit papain-like protease of severe acute respiratory" exact="syndrome" post="coronavirus. Biol. Pharm. Bull.2012, 35, 2036â€&quot;2042. 10.1248/bpb.b12-00623.22971649 ParkJ.-Y.; YukH."/>
  <result pre="AndersonL. J.; BelliniW. J.; FarzanM.; MarascoW. A.Potent neutralization of severe" exact="acute" post="respiratory syndrome (SARS) coronavirus by a human MAb to"/>
  <result pre="J.; BelliniW. J.; FarzanM.; MarascoW. A.Potent neutralization of severe acute" exact="respiratory" post="syndrome (SARS) coronavirus by a human MAb to S1"/>
  <result pre="BelliniW. J.; FarzanM.; MarascoW. A.Potent neutralization of severe acute respiratory" exact="syndrome" post="(SARS) coronavirus by a human MAb to S1 protein"/>
  <result pre="KwonS.Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus Oc43" exact="infection" post="of Mrc-5 human lung cells. Biomolecules2019, 9, 69610.3390/biom9110696. NgA."/>
 </snippets>
</snippetsTree>
